In breast cancer and non-small cell lung cancer, targeting STAT6 or using STAT6 inhibitors can enhance radiosensitivity and reduce M2 polarization of macrophages (He et al., 2023; Nie et al., 2023). The gene discussed is STAT6; the disease is non-small cell lung carcinoma.